While the approval of any KRAS exon 2 p.G12C-specific inhibitor would potentially result in a further 10–15% of the patients with non-squamous NSCLC becoming eligible for targeted therapy (the same proportion currently eligible for EGFR inhibitors), the individual impact of each other driver seems more limited. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.